Illumina, Inc. $ILMN Stock Sold by Howard Capital Management LLC

Howard Capital Management LLC trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 43.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,204 shares of the life sciences company’s stock after selling 76,106 shares during the period. Howard Capital Management LLC’s holdings in Illumina were worth $27,424,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. V Square Quantitative Management LLC acquired a new position in Illumina in the third quarter valued at $525,000. Ninety One UK Ltd boosted its position in Illumina by 37,920.0% during the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock valued at $372,198,000 after acquiring an additional 1,356,397 shares during the last quarter. Ninety One SA Pty Ltd acquired a new stake in Illumina during the 3rd quarter worth about $305,000. Ninety One North America Inc. acquired a new stake in Illumina during the 3rd quarter worth about $4,493,000. Finally, Curated Wealth Partners LLC acquired a new stake in Illumina during the 3rd quarter worth about $840,000. 89.42% of the stock is owned by institutional investors.

Illumina Stock Down 2.0%

Illumina stock traded down $5.39 during midday trading on Friday, hitting $262.54. 2,488,994 shares of the stock were exchanged, compared to its average volume of 4,371,835. Illumina, Inc. has a 52-week low of $94.00 and a 52-week high of $309.35. The stock has a market capitalization of $39.64 billion, a price-to-earnings ratio of 48.98, a price-to-earnings-growth ratio of 3.79 and a beta of 1.41. The business’s 50-day moving average price is $234.53 and its 200-day moving average price is $186.01. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. Illumina’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director owned 770,350 shares of the company’s stock, valued at $168,244,440. The trade was a 13.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 2,061,850 shares of company stock valued at $436,479,102. Insiders own 2.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Royal Bank Of Canada boosted their price objective on Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. Citigroup increased their target price on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. Finally, Barclays lifted their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research report on Wednesday, October 7th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $225.94.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.